Loncar Cancer Immunotherapy ETF (CNCR) Reaches $24.14 Formed H&S; Atossa Genetics (ATOS) SI Increased By 17.8%

Atossa Genetics Inc. (NASDAQ:ATOS) Logo

Atossa Genetics Inc (NASDAQ:ATOS) had an increase of 17.8% in short interest. ATOS’s SI was 3.55 million shares in June as released by FINRA. Its up 17.8% from 3.01M shares previously. With 1.91 million avg volume, 2 days are for Atossa Genetics Inc (NASDAQ:ATOS)’s short sellers to cover ATOS’s short positions. The stock decreased 3.51% or $0.08 during the last trading session, reaching $2.2. About 183,164 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 41.40% since June 30, 2017 and is downtrending. It has underperformed by 53.97% the S&P500. Some Historical ATOS News: 27/04/2018 – INTRACOASTAL CAPITAL LLC REPORTS 5.9 PCT PASSIVE STAKE IN ATOSSA GENETICS INC, AS OF APRIL 23, 2018 – SEC FILING; 08/03/2018 Atossa Genetics Announces 2017 Financial Results and Provides Company Update; 24/04/2018 – Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men; 23/04/2018 – Atossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering; 24/04/2018 – Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation; 23/04/2018 – Atossa Genetics lnforms Stockholders of Key Dates and Terms Related to Announced Rights Offering; 24/04/2018 – ATOSSA GENETICS – INDEPENDENT SAFETY COMMITTEE REVIEWED BLINDED DATA FROM FIRST GROUP IN STUDY, CONCLUDED STUDY MAY ADVANCE TO NEXT DOSING LEVEL

Loncar Cancer Immunotherapy ETF (CNCR) formed H&S with $22.69 target or 6.00% below today’s $24.14 share price. Loncar Cancer Immunotherapy ETF (CNCR) has $70.29M valuation. The ETF increased 0.58% or $0.14 during the last trading session, reaching $24.14. About 14,498 shares traded. Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) has risen 25.36% since June 30, 2017 and is uptrending. It has outperformed by 12.79% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $6.19 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Among 2 analysts covering Atossa Genetics (NASDAQ:ATOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atossa Genetics had 2 analyst reports since January 26, 2018 according to SRatingsIntel. On Friday, January 26 the stock rating was initiated by Maxim Group with “Buy”.

More notable recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018, also Nasdaq.com with their article: “Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board” published on June 14, 2018, Streetinsider.com published: “Atossa Genetics (ATOS) Announces Opening of Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast …” on June 26, 2018. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” published on June 19, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” with publication date: June 15, 2018.